Haloperidol Ratiopharm (Haloperidol)

Haloperidol Ratiopharm is indicated for several psychiatric and neurologic conditions where dopamine blockade is therapeutic.

• Schizophrenia, including maintenance treatment of acute and chronic phases.
• Acute psychotic episodes associated with bipolar disorder or other mental health disorders.
• Severe agitation or aggression that requires rapid control, often in emergency settings.
• Tourette syndrome, particularly when symptoms are refractory to first‑line therapies.
• Pre‑operative sedation or management of delirium in certain clinical situations.

Side‑effect profiles for haloperidol include both frequent, generally mild reactions and less common, potentially serious events.

Common

• Drowsiness or sedation.
• Extrapyramidal symptoms such as tremor, rigidity, or akathisia.
• Dry mouth and increased salivation.
• Constipation or gastrointestinal discomfort.

Serious

• Neuroleptic malignant syndrome, a life‑threatening reaction.
• Tardive dyskinesia with long‑term use.
• Cardiac arrhythmias, including QT‑interval prolongation.

Clinicians should evaluate several safety considerations before prescribing Haloperidol Ratiopharm.

• Assess patient history for cardiovascular disease, especially prolonged QT interval.
• Use the lowest effective dose and limit duration to reduce risk of extrapyramidal side effects.
• Monitor for signs of neuroleptic malignant syndrome, especially after rapid dose escalation.
• Caution in patients with hepatic or renal impairment; dose adjustments may be required.
• Avoid use during pregnancy or lactation unless benefits outweigh risks, as safety data are limited.
• Evaluate for coexisting movement disorders, such as Parkinson’s disease, which may be worsened.

Haloperidol can interact with other medicines, altering its effectiveness or increasing toxicity.

Avoid

• Other dopamine antagonists or antipsychotics, which may amplify extrapyramidal effects.
• Medications that prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics).
• Strong CYP3A4 inhibitors such as ketoconazole or clarithromycin, which can raise haloperidol levels.

Use with caution

• CNS depressants including benzodiazepines or opioids, which may increase sedation.
• Anticholinergic agents, which can mask early signs of extrapyramidal symptoms.
• Lithium, due to potential additive neurotoxic effects.